| Item | NexLife | Henry Meds |
|---|---|---|
| What you get | Compounded semaglutide and tirzepatide (not FDA-approved) | Compounded GLP-1s (not FDA-approved) |
| Program or membership fee | None (“No memberships or contracts”) | Not stated separately; the page gives one “starts at” price |
| Medication included in that price | Yes: medication, medical guidance from NexLife Medical Group, nutrition plan, coaching call, 24/7 support, shipping | Not stated on the page we read |
| Pharmacies named | Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux’s New Drug Store (Lake Charles, LA): 503A | Not checked in this update |
| 12-month arithmetic | Tirzepatide: $115 × 12 = $1,380. Semaglutide: $95 × 12 = $1,140 (12-month plans). | Floor only: $179 × 12 = $2,148 if the starting price applied every month; dose-specific prices were not printed. |
| Price read status | Re-read November 6, 2026 (nexlife.us) | Re-read October 15, 2026 (henrymeds.com GLP-1 page; tirzepatide page 404) |
| Score | 94/100 (v4.1 methodology) | 78/100 (May 2026 review (v3.0 rubric); v4.1 re-score pending) |
Who each program fits
Henry Meds may fit if you want a compounded program and are comfortable confirming dose-specific prices during intake.
NexLife may fit if you want a compounded GLP-1 at a fixed monthly price that does not rise with the dose, with the pharmacy named before you pay. NexLife is not the lowest-priced program we track: Mondae ($126 tirzepatide, $87 semaglutide) lists lower month-to-month prices, and Eden Health ($99) a lower semaglutide price.
Brand medications such as Wegovy and Zepbound are FDA-approved; compounded semaglutide and tirzepatide are not FDA-approved and are not the same products.
What this comparison cannot tell you
We compared published prices and terms, not clinical quality. We did not enroll with either program, so intake-only fees, the pharmacy on a given shipment and dose-specific prices shown after checkout were not visible. Confirm each figure on the program’s own page before paying.